https://mindmedicinelaw.com/briefing/modest-antisuicidal-effects-from-repeated-ketamine-in-trd-no-biomarker-breakthro-20261002-46341The Psychedelic Journalen2026-10-03T15:05:37.268342+00:00Modest Antisuicidal Effects from Repeated Ketamine in TRD: No Biomarker Breakthroughketamine, treatment-resistant depression, suicidal ideation, biomarkers, clinical trials, plasma biomarkers, open-label study, psychiatric research, antisuicidal effectshttps://mindmedicinelaw.com/briefing/neurospirituality-in-clinical-neuroscience-evidence-gaps-and-implications-20261001-46297The Psychedelic Journalen2026-10-03T15:05:58.804547+00:00Neurospirituality in Clinical Neuroscience: Evidence, Gaps, and Implicationsneurospirituality, spirituality and neuroscience, clinical trials, palliative care, default mode network, psychedelic research, meaning-making, regulatory science, existential well-beinghttps://mindmedicinelaw.com/briefing/neonatal-ketamine-dexmedetomidine-and-caspase-1-implications-for-neuroprotection-20261001-46235The Psychedelic Journalen2026-10-02T22:05:16.550694+00:00Neonatal Ketamine, Dexmedetomidine, and Caspase-1: Implications for Neuroprotectionketamine neurotoxicity, dexmedetomidine neuroprotection, caspase-1 modulation, pediatric anesthesia safety, pyroptosis, neurodevelopmental outcomes, clinical trial design, NMDA antagonists, FDA pediatric guidelineshttps://mindmedicinelaw.com/briefing/systematic-review-ketamine-s-psychiatric-role-safety-and-policy-gaps-20261001-46182The Psychedelic Journalen2026-10-02T22:04:54.625001+00:00Systematic Review: Ketamine’s Psychiatric Role, Safety, and Policy Gapsketamine, systematic review, psychiatric applications, treatment-resistant depression, telehealth prescribing, safety considerations, off-label use, NMDA receptor antagonists, public health policy, ethical challengeshttps://mindmedicinelaw.com/briefing/agarikon-index-mapping-psychedelic-clinics-trials-and-law-20261001-46169The Psychedelic Journalen2026-10-02T22:04:41.771414+00:00Agarikon Index: Mapping Psychedelic Clinics, Trials, and Lawagarikon, psychedelic clinics, clinical trials, psychedelic legislation, data aggregation, legal status mapping, regulatory compliance, psychedelic industry, policy analysishttps://mindmedicinelaw.com/briefing/agarikon-index-sets-new-standard-for-psychedelic-medicine-data-20261001-46170The Psychedelic Journalen2026-10-02T22:04:27.239857+00:00Agarikon Index Sets New Standard for Psychedelic Medicine Dataagarikon, psychedelic medicine, data quality, clinical trials, legal status, policy analysis, screened index, auditable data, global clinics, research infrastructurehttps://mindmedicinelaw.com/briefing/agarikon-index-sets-new-standard-for-psychedelic-medicine-data-20261001-46168The Psychedelic Journalen2026-10-02T22:04:14.146034+00:00Agarikon Index Sets New Standard for Psychedelic Medicine Dataagarikon index, psychedelic medicine data, clinical trials registry, legal-status tagging, policy analysis, due diligence, data provenance, health data transparency, sector mapping, screened directorieshttps://mindmedicinelaw.com/briefing/self-medication-with-psychedelics-risks-and-policy-implications-20261001-45959The Psychedelic Journalen2026-10-01T22:04:05.099677+00:00Self-Medication with Psychedelics: Risks and Policy Implicationsself-medication, psychedelics, public health, harm reduction, policy, clinical trials, psychiatric risk, regulation, adverse eventshttps://mindmedicinelaw.com/briefing/ssdp-mobilizes-to-shape-fda-psychedelic-drug-comment-period-20261001-45982The Psychedelic Journalen2026-10-01T22:03:50.612576+00:00SSDP Mobilizes to Shape FDA Psychedelic Drug Comment Periodssdp, fda psychedelic regulations, public comment process, grassroots drug policy, federal policymaking, psychedelic advocacy, regulatory frameworks, youth engagement, community organizations, drug policy reformhttps://mindmedicinelaw.com/briefing/self-medication-of-adhd-with-psychoactive-substances-evidence-and-framing-in-adu-20260930-46299The Psychedelic Journalen2026-10-03T15:06:20.482398+00:00Self-Medication of ADHD with Psychoactive Substances: Evidence and Framing in Adult Populationsadhd, self-medication hypothesis, psychoactive substances, adult mental health, substance use motives, nicotine and adhd, cannabis research, clinical screening, policy implications, harm reductionhttps://mindmedicinelaw.com/briefing/ketamine-s-antidepressant-and-anti-alcohol-mechanisms-in-aud-preprint-review-20260930-46336The Psychedelic Journalen2026-10-03T15:06:09.313608+00:00Ketamine’s Antidepressant and Anti-Alcohol Mechanisms in AUD: Preprint Reviewketamine, alcohol use disorder, mechanism of action, antidepressant effects, clinical trials, NMDA receptor, memory reconsolidation, preprint research, regulatory policyhttps://mindmedicinelaw.com/briefing/emerging-drug-checking-technologies-in-canada-policy-and-practice-outlook-20260929-46315The Psychedelic Journalen2026-10-03T15:05:48.685040+00:00Emerging Drug-Checking Technologies in Canada: Policy and Practice Outlookdrug-checking technologies, harm reduction, canada drug policy, portable spectroscopy, novel psychoactive substances, public health surveillance, unregulated drug supply, implementation challenges, equity in healthcare, machine learning in drug analysishttps://mindmedicinelaw.com/briefing/adverse-outcomes-of-major-psychedelics-us-cross-sectional-data-20260929-46306The Psychedelic Journalen2026-10-03T15:05:24.680857+00:00Adverse Outcomes of Major Psychedelics: US Cross-Sectional Dataadverse events, psychedelics, psilocybin, LSD, MDMA, ibogaine, 5-MeO-DMT, public health, clinical risk, drug policyhttps://mindmedicinelaw.com/briefing/psilocybin-for-trd-phase-3-evidence-safety-and-eu-access-models-20260929-46307The Psychedelic Journalen2026-10-03T15:05:11.679127+00:00Psilocybin for TRD: Phase 3 Evidence, Safety, and EU Access Modelspsilocybin, treatment-resistant depression, phase 3 trials, safety concerns, germany compassionate use, eu regulation, clinical implementation, digital therapeutics, neuroplasticity, HPPDhttps://mindmedicinelaw.com/briefing/phase-1-results-oral-ketamir-2-safety-and-pk-in-healthy-adults-20260929-46338The Psychedelic Journalen2026-10-03T15:05:00.116882+00:00Phase 1 Results: Oral Ketamir-2 Safety and PK in Healthy Adultsketamir-2, nmda antagonist, phase 1 trial, neuropathic pain, oral administration, safety profile, pharmacokinetics, non-dissociative, psychoplastogen pipelinehttps://mindmedicinelaw.com/briefing/psilocybin-and-egocentricity-in-aud-pilot-rct-insights-nct06235411-20260929-46172The Psychedelic Journalen2026-10-02T22:05:05.331814+00:00Psilocybin and Egocentricity in AUD: Pilot RCT Insights (NCT06235411)psilocybin, alcohol use disorder, egocentric bias, social cognition, pilot randomized controlled trial, clinical trial NCT06235411, psychedelic-assisted therapy, mechanism of action, public health, substance use disordershttps://mindmedicinelaw.com/briefing/s-propargyl-l-cysteine-mitigates-ketamine-induced-effects-in-mice-20260922-46068The Psychedelic Journalen2026-10-02T15:05:36.045494+00:00S-propargyl-L-cysteine Mitigates Ketamine-Induced Effects in Mices-propargyl-l-cysteine, ketamine, neuroinflammation, nf-kb, nlrp3 inflammasome, psychedelic safety, preclinical research, adjunctive therapy, pyroptosis, psychiatric therapeuticshttps://mindmedicinelaw.com/briefing/psychedelics-and-suicidality-clinical-risks-and-policy-implications-20260919-46069The Psychedelic Journalen2026-10-02T15:05:20.511221+00:00Psychedelics and Suicidality: Clinical Risks and Policy Implicationspsychedelics, suicidality, clinical trial safety, psychiatric risk, policy implications, harm reduction, screening protocols, serotonergic system, trial ethicshttps://mindmedicinelaw.com/briefing/psilocybin-restores-social-behavior-in-sapap3-knockout-mice-implications-for-neu-20260917-45218The Psychedelic Journalen2026-10-01T22:04:17.836685+00:00Psilocybin Restores Social Behavior in SAPAP3 Knockout Mice: Implications for Neuropsychiatric Researchpsilocybin, SAPAP3 knockout mice, social behavior, prefrontal-hippocampal circuitry, neuropsychiatric disorders, OCD, ASD, preclinical research, biomarkers, clinical trial design